In line with this, the alterations of the human MYO16; either single nuclear polymorphisms (SNPs), deletions or epigenetic modifications are associated with neurodegenerative and neuropsychiatric disorders, including schizophrenia, autism spectrum disorder (ASD), bipolar disorder subtype II (BP-II) and major depressive disorder (MDD) (Table 1) [21,22,23,24,25]. This evidence concerns the gene MYO16 and autism spectrum disorder.